Indole-3-propionic acid supplementation for relapsing-remitting MS
Official title: Indole-3-PROpionic Acid Clinical Trials - Multiple Sclerosis (iPROACT-MS)
Run by Glostrup University Hospital, Copenhagen · NCT07318129 · Data updated 2026-11-12
This trial tests whether taking oral indole-3-propionic acid (a gut-derived supplement) can help protect people with relapsing‑remitting MS from disease activity, nerve damage, and related metabolic problems.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 65 Years |
| Sex | All |
| Enrollment | 220 (estimated) |
| Sponsor | Glostrup University Hospital, Copenhagen Academic / other |
| Locations | 1 site (Glostrup Municipality) |
| Status | Recruiting |
| Started | January 26, 2026 |
| Main results expected | July 15, 2028 |
| Study ends | July 15, 2028 |
| Registry record updated | January 28, 2026 |
| Trial ID | NCT07318129 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18–65 with relapsing‑remitting MS by McDonald criteria who are routinely treated and monitored for MS and can read and speak Danish are the intended participants.
✕Probably not a fit
People with progressive MS, active malignancy, inflammatory bowel disease, significant comorbidities, pregnancy or lactation, or MR contraindications are unlikely to be eligible or to benefit from this intervention.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional trial gives adults with relapsing‑remitting MS daily oral indole‑3‑propionic acid (IPA) or a matching placebo while monitoring clinical and biological outcomes. Participants undergo clinical follow-up, MRI scans, and laboratory tests to track MS disease activity, neurodegeneration markers, inflammation, oxidative stress, metabolic measures, and gut microbiome profiles. Secondary analyses will examine how lifestyle and gut microbial factors relate to inflammation, metabolic health, and MS severity. The trial is led at Glostrup Hospital in collaboration with the University of Copenhagen and the University of Southampton.
Why it matters
Potential benefit: If successful, IPA supplementation could reduce MS relapses and slow neurodegeneration while improving metabolic and inflammatory profiles.
How similar studies have gone: Preclinical studies and small human investigations of IPA and related gut-derived metabolites suggest neuroprotective and anti‑inflammatory effects, but oral IPA supplementation in RRMS remains largely untested in larger clinical trials.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Women and men ≥18 and ≤65 years of age * Diagnosed with RRMS according to the 2017 McDonald criteria (or newer updates) * Routinely treated and monitored for MS * Speak and read Danish * Deemed physically and mentally able to participate in this study Exclusion Criteria: * Active malignancy * Diagnosis of Crohn's disease and ulcerative colitis * Other comorbidities deemed to be relevant * Haematopoietic stem cell transplantation * Current or past treatment with non-MS related treatments deemed to be relevant * Pregnancy or lactation * People with MR contraindications: * Severe claustrophobia * Incompatible implants/ foreign objects, including implanted pacemakers, heart valve prostheses, prostheses in the middle ear, implanted devices (e.g., insulin pump), metal debris, e.g., metal splinters in the eyes, miscellaneous shunts and catheters, metal clips from operations
Where it's running
-
Glostrup Hospital
Glostrup Municipality, Denmark Recruiting
Study contacts
- Principal investigator: Jette Lautrup Frederiksen, MD, dr.med, professor — Copenhagen University Hospital, Rigshospitalet-Glostrup
- Study coordinator: Jette Lautrup Frederiksen, MD, dr.med, professor
- Email: jette.lautrup.battistini@regionh.dk
- Phone: +4538633041
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Rocbrutinib in PRL-Positive Relapsing-Remitting MS
This study tests whether Rocbrutinib can help people with relapsing-remitting MS who have paramagnetic rim lesions, compared to dimethyl fumarate.
-
BCD-281 versus ocrelizumab for relapsing-remitting multiple sclerosis
This study tests whether BCD-281 works as well and is as safe as ocrelizumab for adults 18–55 with relapsing‑remitting multiple sclerosis.
-
Anti-CD20 maintenance vs. de-escalation in relapsing-remitting MS
This trial tests whether continuing anti-CD20 therapy at standard maintenance is as good as a de-escalated approach in people with relapsing-remitting MS who have been on anti-CD20 treatment for at least 3 years.
-
Using eye movement biomarkers to track disease changes in active RRMS patients
This study is testing if tracking eye movements can help doctors see how well a new treatment works for people with active Relapsing Remitting Multiple Sclerosis.
-
Imaging axonal damage and repair in multiple sclerosis
This study is testing new MRI techniques to see how axons are damaged and repaired in people with multiple sclerosis over two years.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.